Abstract: The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.

Abstract: The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of ?APP or of the activity of the A? peptide in the choroid plexus.

Abstract: An EIT or differential EIT method in which measurements of voltage differences between electrodes are performed according to a measurement configuration in which at least one of the electrodes injecting a current in the medium being investigated is also used for performing a measurement of the voltage difference. The contact impedances of the different electrodes are measured thanks to a counter-electrode having a contact area with the medium much higher than the contact area of a unit electrode. The measurement of a contact impedance is performed by impedance spectroscopy by comparison with the impedance spectrum of an equivalent circuit. The contact impedances allow voltage drops in the injection electrodes to be calculated the voltage differences between these electrodes and to be corrected. Alternatively, the contact impedances can be used to correct or complete the direct model.

Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.

Abstract: A method, an apparatus, and a computer program product for wireless communication are provided. The apparatus determines an observed bit rate based on uplink transmissions of the UE, estimates an available link capacity for the UE, selects an estimate factor, and estimates available uplink throughput for future uplink transmissions of the UE as a function of the observed bit rate, the estimated available link capacity, and the estimate factor.

Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.

Abstract: A microscope for high spatial resolution imaging a structure of interest in a sample comprising a substance having a first state with first spectral properties and a second state with second spectral properties, the microscope comprising: an objective-lens assembly, a wave front modulating optical device adapted to spatially vary an intensity of a transfer light beam, a probe detector arranged to detect an optical measurement signal from a portion of the substance in the second state and placed in an area of the transfer light beam with an intensity adapted not to transfer the substance between the first and second states said microscope comprising a phase contrast microscopy system which includes an intensity detector arranged to detect an intensity of an illuminating light beam after said illuminating light beam has passed through the sample, the objective-lens assembly and the wave front modulating optical device.

Abstract: The present invention relates to a method for detecting the presence of carbapenemase-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —a carbapenemase substrate selected from the group consisting of carbapenems and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of carbapenemase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of carbapenemase producers in a test sample.

Abstract: The present invention also relates to an antisense oligonucleotide complementary to a nucleic acid sequence of COL7A1 gene that is necessary for correct splicing of one or more exons which encode amino acid sequence of type VII collagen implicated in dysfunction of a mutated type VII collagen wherein said exons are selected from the group consisting of exon 73, 74 or 80 of the COL7A1 gene. The present invention also relates to a method for the treatment of a patient suffering from Dystrophic Epidermolysis Bullosa caused by a dysfunction of a mutated type VII collagen, comprising the step of administering to said patient a least one antisense oligonucleotide according to the invention.

Abstract: The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system.

Abstract: A method of high-resolution ultrasound imaging, in which transducers are made to emit ultrasound waves in a field of observations containing micro bubbles, by making the micro bubbles burst one by one in tandem with the emissions of ultrasound waves. At each shot j of an ultrasound wave, raw reverberated signals Sj(i,t) picked up by each transducer i are recorded, and then differential signals Vj(i,t) representative of variations between successive raw signals are determined, a parabolic function Pj(x) is fitted to the differential signals corresponding to each shot j, and then a crest Aj(x0,y0) of this function Pj, corresponding to the position of the micro bubble destroyed between shots j?1 and j, is determined.

Abstract: The present invention relates to a culture medium comprising a carbapenem, a carbapenemase activator and a M-type penicillin. It also relates to a method for detecting carbapenem-resistant bacteria in a test sample using said culture medium.

Abstract: The use of substance selected from taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis, for preventing or inhibiting the undesirable side-effects caused to a human or an animal organism by an active ingredient that induces a high level of extracellular GABA or increases GABA receptor activation, and a pharmaceutical composition including the substance and the active ingredient.

Abstract: The present invention provided methods and compositions for generating novel nucleic acid molecules through targeted spliceosome mediated simple or double trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and to mediate a simple or double trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (Chimeric RNA).

Abstract: Provided is a method for preparing nanocapsules having a liquid lipid core and a solid shell and charged in their lipid core with at least one hydrophilic active agent involving combining microemulsions where the active agent remains in the hydrophilic phase of a first microemulsion and chill-hardening the mixture to obtain the nanocapsules charged with the hydrophilic active agent. The nanocapsules comprise the lipid core which is liquid at room temperature and the nanocapsules are encapsulated in a film which is solid at room temperature.

Abstract: The present invention concerns an in vitro method for diagnosing a myeloid tumor or a lymphoid tumor in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumor or a lymphoid tumor.

Abstract: The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mineralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing.

Abstract: The present invention relates to antibodies which bind human ghrelin and their use in methods of treating or preventing reduced appetite. The invention further relates to diagnostic tools for determining whether an individual is likely to respond to a method of treating or preventing reduced appetite.

Abstract: The invention concerns: —a silylated biomolecule having the following formula (I): —the process for the preparation of a silylated biomolecule of formula (I), —the use of a silylated biomolecule of formula (I) to functionalize the surface of a support, —a process for the preparation of a hydrogel by use of a silylated biomolecule of formula (I), the hydrogel obtainable by said process, —said hydrogel as a biological tissue substitute, —a composition comprising said hydrogel in a pharmaceutically acceptable vehicle, —said composition for the release of active principle.

Abstract: The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.